30 closest matches · ranked by relevance
Pseudomonas Aeruginosa
Primary: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa — 18.1; 12.5; 22.4 Percentage of participants — p=0.491
Staphylococcus Aureus Pneumonia
Primary: Percentage of Participants With Endpoint Adjudication Committee-Determined (EAC) Staphylococcus Aureus (S Aureus) Pneumonia — 26.0; 20.0; 17.7 Percentage of Participants…
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 2; 6; 8 Participants
Cystic Fibrosis
Primary: Time to an Exacerbation — 58; 51.5 Days — p=0.0715
Cystic Fibrosis (CF)
Primary: Change in P. Aeruginosa Density — 0.23; -0.31; -0.31; -0.73 log10 CFU/g sputum — p=0.0014
Cystic Fibrosis
Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 90; 180 participants
Chronic Obstructive Pulmonary Disease
Primary: Exacerbation Rate — 1.20; 1.31 exacerbation per patient year — p=0.7282
Pneumonia, Bacterial
Primary: Change From Baseline in Clinical Pulmonary Infection Score (CPIS) For Each Patient, Value Obtained From a Daily Assessment Over the 10 Day Study Period Was Compared to…
Cystic Fibrosis
Primary: Percentage of Participants With PA-negative Cultures at All Time Points After Cessation of Active Treatment (Evaluable Analysis Set) — 58.2 percentage of participants
Cystic Fibrosis · Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization — 24; 26; 29; 21 number of participants — p=0.86
Non Cystic Fibrosis Bronchiectasis
Primary: Mean Annual Non-cystic Fibrosis Bronchiectasis (NCFB) Pulmonary Exacerbation Rate — 0.580; 0.948 number of Pulmonary Exacerbations — p=0.00101
Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population — 15.9; 21.3 Percentage of participants…
Cystic Fibrosis
Primary: Time to Recurrence of Pseudomonas (P.) Aeruginosa (Any Genotype) in Sputum or Deep Throat Cough Swab — 26.12; 25.82 Months
Hospital-Acquired Bacterial Pneumonia · Ventilator-Associated Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality Through Day 28 in the Modified Intent to Treat (MITT) Population — 11.2; 5.9 Percentage of Participants — p=0.024
Pneumonia
Primary: Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population — 103; 95 Participants
Pulmonary Cystic Fibrosis
Primary: Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day — 13.30; 13.83 percentage change — p=0.0164
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
Community-acquired Pneumonia (CAP) · Hospital-acquired Pneumonia (HAP)
Primary: Adverse Events — 10; 5; 1; 0 Participants
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Primary: Day 14 All-cause Mortality Rate — 3.0; 2.7 percentage of participants
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Healthcare-Associated Pneumonia · Ventilator-Associated Pneumonia · Lung Diseases
Primary: Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28 — 24.0; 25.3 Percentage of Participants
Cystic Fibrosis
Primary: Absolute Change in Forced Expiratory Volume at One Second (FEV1) % Predicted Between Study Arms With Acute Pulmonary Exacerbation (APE) Treatment — 6.5; 4.4; 4.5 ppFEV1
Respiratory Viral Infections · Respiratory Syncytial Virus Infections · Parainfluenza Virus 3, Human
Primary: Number of Participants With Solicited Adverse Events (SEs) After Dose 1 — 12; 5; 8; 6 participants
Chronic Obstructive Pulmonary Disease
Primary: To Evaluate the Rate of Severe Exacerbations in COPD, Comparing COPD Patients Previously Treated According to the PRO-CT Protocol Versus COPD Patients Previously Treated…
Non-cystic Fibrosis Bronchiectasis · Pseudomonas Aeruginosa · Lung Infection
Primary: P. Aeruginosa Recovery in Sputum Following Multiple Doses of AP-PA02 Administered by Inhalation — -0.5; -0.1; -0.4; 1.0 colony forming units log10
Cystic Fibrosis
Primary: Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28 — 8.35; 0.55 percent change in FEV1 percent predicted — p=0.0001
Cystic Fibrosis
Primary: Time to a Protocol-defined Pulmonary Exacerbation — 1.350; 0.758 years — p=0.0043